Searchable abstracts of presentations at key conferences in endocrinology

ea0044p208 | Reproduction | SFEBES2016

Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) are predictive markers in the assessment of patients with menstrual disturbance

Abbara Ali , Clarke Sophie , Roberts Rachel , Vimalesvaran Sunitha , Comninos Alexander , Christopoulos Georgios , Islam Rumana , Franks Steven , Trew Geoffrey , Dhillo Waljit

Background: Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) are both principally used as markers of ovarian reserve and available in all UK hospitals. The utility of these markers in the binary diagnosis of Polycystic Ovarian Syndrome (PCOS) by published criteria, such as Rotterdam, has been previously reported. We evaluated their utility in the evaluation of oligo/amenorrhoea in healthy young non-obese women.Methods: Women with both ov...

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...

ea0050oc1.1 | Early Career Oral Communications | SFEBES2017

Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Lin Vivian , Stern Theresa , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes (HF) affect 70% of menopausal women and can be debilitating. Oestrogen administration is effective but not without risk. Neurokinin B signalling is increased in menopausal women, and is likely critical in the aetiology of their HF. We therefore hypothesised that a neurokinin 3 receptor (NK3R) antagonist could attenuate menopausal flushing.Design: This single-centre, phase 2, randomised, double-blind, placebo-controlled, crossover ...

ea0049gp131 | Female Reproduction | ECE2017

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes affect 70% of menopausal women, can be long-lasting, and often severely impact on physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but not without risk. Neurokinin B is an important mediator of hot flushes in rodents and elevated hypothalamic expression occurs in menopausal women. Neurokinin B acts via the neurokinin 3 receptor. We therefore hypothesised that neurokinin 3 receptor antagonism could be a nove...

ea0044oc6.1 | Pregnancy and Reproductive Health | SFEBES2016

Two doses of kisspeptin improve oocyte maturation and implantation rates compared to a single kisspeptin injection during IVF treatment

Abbara Ali , Clarke Sophie , Islam Rumana , Prague Julia , Comninos Alexander , Narayanaswamy Shakunthala , Papadopolou Deborah , Roberts Rachel , Nesbitt Alexander , Izzi-Engbeaya Chioma , Vimalesvaran Sunitha , Ratnasabapathy Risheka , Salim Rehan , Lavery Stuart , Bloom Stephen , Trew Geoffrey , Dhillo Waljit

Background: In vitro fertilisation is an effective therapy for infertility, but can result in the potentially life-threatening complication, Ovarian Hyper-Stimulation Syndrome (OHSS). We have previously reported that a single injection of kisspeptin results in an LH surge of ~12–14 hrs duration, sufficient to safely induce oocyte maturation, but eliminate OHSS. However, the physiological LH surge in a normal menstrual cycle has a plateaux lasting 24–28 hrs. ...